KQB365 for advanced solid tumors with KRAS mutations
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that cannot be removed with surgery or has spread to other parts of the body.
- Your tumor must have a KRAS G12C or KRAS G12S gene change.
- You must have tried or not be able to have other treatments that could cure the cancer.
- You need to have tumors that can be measured on scans.
- Your organs (like kidneys, liver, and bone marrow) must be working well enough.
- You cannot have active lung disease, serious heart problems, or active brain tumors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug (KQB168) given alone or with other medicines for people with advanced solid tumors that have not responded to immunotherapy. The goal is to see if it is safe and can help shrink or slow the growth of cancer.
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Hear when a new KRAS G12C Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.